ClinicalTrials.gov
public full text
Public Domain
RAAS Inhibitor Drugs in Dialysis Patients
Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients#1030342
- The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis#874435
- Study of Haemodialysis Patients Switching From Aranesp to Biosimilar#1101234
- T-Wave Alternans in Dialysis Patients#831391
- ACEi ARB Withdrawal in CKD Patients#1163284
Record · ID 1009475
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive